


CLAIMS

1. A method for the treatment or prevention of osteoporosis in an individual suffering from increased bone turnover, said method comprising administering to said individual an effective amount of a therapeutically active compound, which is a selective estrogen receptor modulator of triphenylalkene or triphenylalkane structure.
2. The method according to claim 1 wherein the therapeutically active compound is a compound of the formula (I)



(I)

or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

3. The method according to claim 2 wherein compound (I) is ospemifene.
4. The method according to claim 1, wherein the individual is a postmenopausal woman.
5. The method according to claim 1, wherein the increased bone turnover is a bone resorption and a bone formation being at least 5 %, preferably at least 10 % higher than the normal values for these markers.
6. The method according to claim 1 wherein the individual has
 - a) a bone resorption of at least 65 nmol/mmol Creatine, using amino terminal telopeptide of type I collagen measured in urine (U-NTX) as marker, and/or at least 680

microgram/mmol Creatine, using carboxy terminal telopeptide of type I collagen measured in urine (U-CTX) as marker, and

b) a bone formation of at least 170 microgram/l, using carboxy terminal propeptide of type I procollagen measured in serum (S-PICP) as marker and/or at least 84 microgram/l, using amino terminal propeptide of type I procollagen measured in serum (S-PINP) as marker.

7. The method according to claim 6 where the bone resorption, measured as U-NTX, is at least 70 nmol/mmol Creatine, and the bone formation, measured as S-PICP, is at least 180 microgram/l.

8. The method according to claim 7 where the bone resorption, measured as U-NTX, is at least 80 nmol/mmol Creatine.

9. The method according to claim 5 wherein the bone resorption has been measured wherein the bone resorption has been measured using as marker Crosslaps measured from serum.

10. The method according to claim 5 wherein the bone resorption has been measured using as marker TRAP5b measured from serum.

11. The method according to claim 5 wherein the bone resorption has been measured using as markers a combination of Crosslaps and TRAP5b, both measured from serum.